A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
Veracyte Announces Second Quarter 2020 Financial Results
<< Back
Jul 30, 2020

Veracyte Announces Second Quarter 2020 Financial Results

Revenue of $20.7 Million and Genomic Testing Volume of 5,379

Company Advances Pipeline and Global Expansion Strategy

Conference Call and Webcast Today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 30, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress.

“We delivered solid second quarter results in the face of headwinds from the COVID-19 pandemic,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “Our genomic testing volume doubled between April and June as hospitals started performing more non-emergency procedures and physician practices began to open. We have begun leveraging opportunities for new virtual sales and marketing models to increase efficiency and drive growth. We also remain on track to bring four new tests to market in 2021, further accelerating our growth. Additionally, we continued to grow our biopharmaceutical and diagnostic partnerships to fuel our global expansion with a comprehensive test menu that extends our total addressable market beyond the $40 billion for our current and pipeline products.”

Second Quarter 2020 Financial Results

For the second quarter of 2020:

  • Total revenue was $20.7 million, comprising $16.9 million in testing and product revenue and $3.8 million in biopharmaceutical partnership and collaboration revenue; 
  • Gross Margin was 63%;
  • Operating Expenses, Excluding Cost of Revenue were $24.1 million;
  • Net Loss and Comprehensive Loss was $11.0 million;
  • Basic and Diluted Net Loss Per Common Share was $0.22;
  • Net Cash Used in Operating Activities was $8.4 million; and
  • Cash and Cash Equivalents were $147.5 million at June 30, 2020.

For the six-month period ended June 30, 2020:

  • Total revenue was $51.8 million, comprising $47.3 million in testing and product revenue and $4.5 million in biopharmaceutical partnership and collaboration revenue;
  • Gross Margin was 62%;
  • Operating Expenses, Excluding Cost of Revenue were $55.2 million;
  • Net Loss and Comprehensive Loss was $22.7 million;
  • Basic and Diluted Net Loss Per Common Share was $0.45; and
  • Net Cash Used in Operating Activities was $13.7 million.

Second Quarter 2020 and Recent Business Highlights

Core Diagnostics Business:

  • Increased our reported genomic testing volume (Afirma, Percepta and Envisia), with June total volume doubling that of April.
  • Expanded virtual customer engagement program, conducting more than two dozen virtual educational events, email campaigns and other digital outreach to clinicians.
  • Strengthened our library of published clinical evidence supporting use of the Afirma Xpression Atlas (Cancer Cytopathology) and the Envisia Genomic Classifier (CHEST and AJRCCM). The AJRCCM study further demonstrates the Envisia classifier’s ability to improve diagnosis of idiopathic pulmonary fibrosis without the need for surgery.
  • LymphMark – Submitted De Novo classification request to the FDA for the lymphoma subtyping test, which is designed to help inform diagnosis and better treatment decisions.
  • On track to launch four new products in 2021: Nasal swab test for early lung cancer detection; Percepta Atlas to inform treatment decisions in lung cancer; Envisia international launch on the nCounter; and LymphMark, if the FDA grants our De Novo classification request.
  • Signed distributor contracts that will make Veracyte’s advanced genomic testing on the nCounter system available to laboratories throughout the Asia Pacific region, as well as in Australia and New Zealand.

Strategic Collaborations:

  • CareDx – Formed strategic collaboration through which CareDx has the exclusive right to develop solid organ transplant rejection tests on the nCounter Analysis System, fueling our global menu expansion.
  • Generated revenue from four biopharmaceutical and diagnostics partners: Eli Lilly/Loxo Oncology, Johnson & Johnson Innovation, Acerta Pharma and CareDx.
  • MAVIDx – Signed strategic agreement, taking an equity stake in MAVIDx, for the new company to develop COVID-19 and other infectious disease tests for ultra-high throughput testing on the nCounter system. A Harvard University report estimates the market will require 20 million tests per day in the United States alone.

Conference Call and Webcast Details

Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/xs86q7qz. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call can be accessed as follows:

U.S./Canada participant dial-in number (toll-free):

(855) 541-0980

International participant dial-in number:

(970) 315-0440

Conference I.D.:

2496566

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding Veracyte’s financial and operational results for the second quarter ended June 30, 2020, anticipated timing of the launch of new products in 2021, availability of Veracyte’s testing internationally, Veracyte’s total addressable market, the current and future impacts of COVID-19 on Veracyte’s business, actions Veracyte has taken in response to COVID-19, and Veracyte’s long-term outlook. Forward-looking statements are neither historical facts nor assurances of future performance, but are based only on our current beliefs, expectations and assumptions. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: the impact of COVID-19 on Veracyte’s business and operating results, specifically, and the healthcare system and economy more generally, Veracyte’s ability to achieve and maintain Medicare coverage for its tests; the benefits of Veracyte’s tests and the applicability of clinical results to actual outcomes; the laws and regulations applicable to Veracyte’s business, including potential regulation by the Food and Drug Administration or other regulatory bodies; Veracyte’s ability to successfully achieve and maintain adoption of and reimbursement for its products; the amount by which use of Veracyte’s products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in Veracyte’s filings with the Securities and Exchange Commission, including the risks set forth in its quarterly report on Form 10-Q for the quarter ended June 30, 2020. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and the Veracyte logo are trademarks of Veracyte, Inc.

 
VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands of dollars, except share and per share amounts)
 
Three Months Ended June 30, Six Months Ended June 30,

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenues:
Testing revenue

$

15,212

 

$

26,686

 

$

42,203

 

$

52,075

 

Product revenue

 

1,713

 

 

 

 

5,122

 

 

 

Biopharmaceutical revenue

 

3,779

 

 

1,450

 

 

4,501

 

 

5,590

 

Collaboration revenue

 

 

 

2,000

 

 

 

 

2,000

 

Total revenue

 

20,704

 

 

30,136

 

 

51,826

 

 

59,665

 

 
Operating expenses:
Cost of testing revenue

 

6,471

 

 

8,777

 

 

17,039

 

 

17,290

 

Cost of product revenue

 

932

 

 

 

 

2,491

 

 

 

Cost of biopharmaceutical revenue

 

252

 

 

 

 

368

 

 

 

Research and development

 

4,169

 

 

3,330

 

 

8,576

 

 

6,765

 

Selling and marketing

 

10,701

 

 

13,943

 

 

28,285

 

 

26,420

 

General and administrative

 

7,957

 

 

6,920

 

 

15,770

 

 

13,824

 

Intangible asset amortization

 

1,273

 

 

266

 

 

2,548

 

 

533

 

Total operating expenses

 

31,755

 

 

33,236

 

 

75,077

 

 

64,832

 

Loss from operations

 

(11,051

)

 

(3,100

)

 

(23,251

)

 

(5,167

)

Interest expense

 

(65

)

 

(235

)

 

(120

)

 

(538

)

Other income, net

 

91

 

 

841

 

 

630

 

 

1,294

 

Net loss and comprehensive loss

$

(11,025

)

$

(2,494

)

$

(22,741

)

$

(4,411

)

Net loss per common share, basic and diluted

$

(0.22

)

$

(0.05

)

$

(0.45

)

$

(0.10

)

Shares used to compute net loss per common share, basic and diluted

 

50,212,123

 

 

45,586,081

 

 

50,002,377

 

 

43,389,540

 

 
VERACYTE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
 
June 30, 2020 December 31, 2019
(Unaudited) (See Note 1)
Assets
Current assets:
Cash and cash equivalents

$

147,450

$

159,317

Accounts receivable

 

15,306

 

19,329

Supplies

 

7,041

 

6,806

Prepaid expenses and other current assets

 

2,891

 

2,235

Total current assets

 

172,688

 

187,687

Property and equipment, net

 

8,640

 

8,933

Right-of-use assets - operating lease

 

8,339

 

8,808

Finite-lived intangible assets, net

 

62,471

 

65,019

Goodwill

 

2,725

 

2,725

Restricted cash

 

603

 

603

Other assets

 

1,271

 

1,437

Total assets

$

256,737

$

275,212

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

$

2,224

$

2,328

Accrued liabilities

 

9,386

 

13,734

Current portion of operating lease liability

 

1,495

 

1,407

Total current liabilities

 

13,105

 

17,469

Long-term debt

 

801

 

694

Acquisition related contingent consideration

 

5,948

 

6,088

Operating lease liability, net of current portion

 

10,736

 

11,506

Total liabilities

 

30,590

 

35,757

Total stockholders’ equity

 

226,147

 

239,455

Total liabilities and stockholders’ equity

$

256,737

$

275,212

 

(1) The condensed balance sheet at December 31, 2019 has been derived from the audited financial statements at that date included in the Company's Form 10-K filed with the Securities and Exchange Commission dated February 25, 2020.

VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited)
(in thousands of dollars)
 
Six Months Ended June 30,

 

2020

 

 

2019

 

Operating activities
Net loss

$

(22,741

)

$

(4,411

)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

 

3,929

 

 

1,869

 

Gain on disposal of property and equipment

 

 

 

(17

)

Stock-based compensation

 

6,265

 

 

4,325

 

Amortization of debt issuance costs

 

 

 

83

 

Interest on end-of-term debt obligations

 

107

 

 

120

 

Write-down of excess supplies

 

1,088

 

 

 

Noncash lease expense

 

469

 

 

431

 

Revaluation of acquisition related contingent consideration

 

(140

)

 

 

Changes in operating assets and liabilities:
Accounts receivable

 

4,023

 

 

(6,458

)

Supplies

 

(1,323

)

 

(1,702

)

Prepaid expenses and other current assets

 

(664

)

 

(192

)

Operating lease liability

 

(682

)

 

(604

)

Other assets

 

166

 

 

25

 

Accounts payable

 

122

 

 

1,746

 

Accrued liabilities

 

(4,343

)

 

1,319

 

Net cash used in operating activities

 

(13,724

)

 

(3,466

)

Investing activities
Purchases of property and equipment

 

(1,314

)

 

(1,424

)

Proceeds from disposal of property and equipment

 

 

 

17

 

Net cash used in investing activities

 

(1,314

)

 

(1,407

)

Financing activities
Proceeds from the issuance of common stock in a public offering, net of issuance costs

 

 

 

137,848

 

Payment of long-term debt

 

 

 

(24,900

)

Payment of financial lease liability

 

 

 

(152

)

Payment of taxes on vested restricted stock units

 

(2,678

)

 

(676

)

Proceeds from the exercise of common stock options and employee stock purchases

 

5,849

 

 

7,405

 

Net cash provided by financing activities

 

3,171

 

 

119,525

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

(11,867

)

 

114,652

 

Cash, cash equivalents and restricted cash at beginning of period

 

159,920

 

 

78,598

 

Cash, cash equivalents and restricted cash at end of period

$

148,053

 

$

193,250

 

 
Supplementary cash flow information of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued liability

$

 

$

72

 

Interest paid on debt

$

3

 

$

319

 

 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH
(Unaudited)
(In thousands of dollars)
 
June 30, 2020 December 31, 2019
Cash and cash equivalents

$

147,450

$

159,317

Restricted cash

 

603

 

603

Total cash, cash equivalents and restricted cash

$

148,053

$

159,920

 

Investor and Media Contact:
Tracy Morris
Vice President of Corporate Communications
& Investor Relations
650-380-4413
tracy.morris@veracyte.com

Source: Veracyte, Inc.